Purpose

The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective cohort of patients who received biopsies.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • From the archive, any patient who presents with clinically evident oral lesions and biopsy-proven dysplasia (punch or scalpel biopsies; any grade or classification system) - Patients with initial oral lesions with epithelial atypia suspicious for neoplasia, with: - No histological evidence of cancer with clinical follow-up data for a period of at least five years; or - OSCC development (histologic or documented evidence of invasive cancer). - Patients who had archived biopsy tissue blocks of a previous oral lesion(s) meeting the above criteria and retained at the same clinical center.

Exclusion Criteria

  • Patients with oral lesions or dysplasia with no indication of OSCC development or follow-up data of less than five years in non-OSCC patients. - Patients diagnosed with oral epithelial dysplasia concomitant with OSCC at the time of the biopsy's original pathology report or a subsequent clinical note of cancer progression within three months post-biopsy.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Arm Groups

ArmDescriptionAssigned Intervention
OPMDs that progressed to OSCC No dysplasia, mild, moderate, severe dysplasia, CIS
  • Other: STRATICYTE™ Test
    Assessment for risk of progression to oral cancer
    Other names:
    • S100A7 Immunohistochemistry Signature-based Test
OPMDs that did not progress to OSCC No dysplasia, mild, moderate, severe dysplasia, CIS
  • Other: STRATICYTE™ Test
    Assessment for risk of progression to oral cancer
    Other names:
    • S100A7 Immunohistochemistry Signature-based Test

Recruiting Locations

MD Anderson Cancer Cetner
Houston, Texas 44907
Contact:
Andrew G Sikora, MD, PhD

More Details

Status
Recruiting
Sponsor
Proteocyte Diagnostics Inc.

Study Contact

Jody Filkowski, BSc, MSc, PhD
1-825-305-0749
Jody.Filkowski@medlior.com

Detailed Description

The study objectives are to: 1. Evaluate STRATICYTE™ sensitivity and specificity in a cohort of patients that meet the inclusion/exclusion criteria. 2. Identify patient and clinical characteristics influencing the sensitivity and specificity of the STRATICYTE™ model. 3. Estimate the correlation between STRATICYTE™ outcome and time to a positive diagnosis of oral cancer.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.